The science of nebulised drug delivery

Effective nebuliser therapy requires a device distinguished from a simple atomiser by the incorporation of baffles which selectively rethat repeatedly and quickly delivers sufficient drug to the site of action, with minimal wastage, move large droplets from the outgoing spray. Early models were essentially atomisers conat a low cost. Clinicians are bombarded with competing claims about different nebuliser sysstructed of glass and operated manually by compressing a hand bulb attached to the air tems. In many cases, however, insufficient details are available to make the most appropriate inlet tube. In 1946 pumps providing a continuous flow of air were advocated and the choice. The rapid increase in the number of nebulisers marketed and significant differences Collinson nebuliser, constructed of ebonite with a plate baffle to filter out particles larger in design may result in drug delivery to patients varying by a factor of two or more. than 5 lm, became the most popular nebuliser in this country. In 1958 Wright described a new nebuliser, considerably more compact than the Collinson, with a moulded perspex top. Drug delivery from nebulisers Most of the prescribed medication for nebuNow discontinued, it found widespread use in bronchial challenge testing. 14 lisers never reaches the lungs. Of the dose placed in the nebuliser chamber, perhaps two With the advent of portable, oil free compressors and injection moulding of plastics, a thirds remains there at the end of nebulisation. Two thirds of the dose released from the nebuwide variety of disposable nebulisers has become available. Recent advances in their liser may be released during expiration and passes into the surrounding air. Some of the design have considerably altered the amount of drug patients receive. inhaled drug will be in particles too large to reach the lung, and some in particles so small that they do not deposit but are simply exhaled again. With many nebulisers only 10% of the    In a jet nebuliser the driving gas passes through prescribed dose may reach the lung. For bronchodilators, where a small dose may a very narrow hole, known as a Venturi, from a high pressure system (fig 1). At the Venturi achieve an adequate result, this may not matter. It is more important for drugs with dose related the pressure falls and the gas velocity increases greatly producing a cone shaped front. This effects (and side effects) such as steroids, and for expensive medications such as rhDNase. passes at high velocity over the end of a narrow liquid feed tube or concentric feeding system creating a negative pressure at this point. As a result of this fall in pressure, liquid is sucked Nebuliser types: how they work Nebulisers used in aerosol drug delivery proup by the Bernoulli effect (see Appendix 1) and is drawn out into fine ligaments. The duce a polydisperse aerosol where most of the drug released is contained in particles 1–5 lm ligaments then collapse into droplets under the influence of surface tension. This primary in diameter. Most nebulisers use compressed air for atomisation (fig 1), but some use ultrageneration (atomisation) typically produces droplets 15–500 lm in diameter. Coarse sonic energy (fig 2). A nebuliser may be

[1]  D. Cockcroft,et al.  Importance of evaporative water losses during standardized nebulized inhalation provocation tests. , 1989, Chest.

[2]  J. Mortensen,et al.  99Technetiumm DTPA does not break down during ultrasound nebulization , 1989 .

[3]  V. Prodi,et al.  Deposition of charged particles in the human airways , 1983 .

[4]  H. Magnussen,et al.  Variability in aerosol output of the DeVilbiss 646 jet nebulizer. , 1992, Chest.

[5]  A. Wilson,et al.  Dose-response effects of two sizes of monodisperse isoproterenol in mild asthma. , 1990, The American review of respiratory disease.

[6]  H. Noteborn,et al.  Drug delivery systems. , 1989, Current opinion in oncology.

[7]  G. Smaldone Deposition patterns of nebulized drugs: is the pattern important? , 1994, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[8]  I Gonda,et al.  Droplets produced by medical nebulizers. Some factors affecting their size and solute concentration. , 1990, Chest.

[9]  C. O’Callaghan Particle size of beclomethasone dipropionate produced by two nebulisers and two spacing devices. , 1990, Thorax.

[10]  M. O'Doherty,et al.  Does inhalation of pentamidine in the supine position increase deposition in the upper part of the lung? , 1990, Chest.

[11]  J S Fleming,et al.  A new method of quantification of the pulmonary regional distribution of aerosols using combined CT and SPECT and its application to nedocromil sodium administered by metered dose inhaler. , 1994, The British journal of radiology.

[12]  J. Mauderly,et al.  ANIMAL STUDIES WITH ENVIRONMENTAL AEROSOLS , 1993 .

[13]  Why nebulise for more than five minutes? , 1989, Archives of disease in childhood.

[14]  O. Selroos,et al.  Effect of a volumatic spacer and mouth rinsing on systemic absorption of inhaled corticosteroids from a metered dose inhaler and dry powder inhaler. , 1991, Thorax.

[15]  S. Clarke,et al.  Effect of nebulised aerosol size on lung deposition in patients with mild asthma. , 1987, Thorax.

[16]  Electrostatic lung deposition experiments with humans and animals. , 1985, The Annals of occupational hygiene.

[17]  D. Hendrick,et al.  Design characteristics for drug nebulizers. , 1992, Journal of medical engineering & technology.

[18]  T. P. Mccarthy Use of 'Nebuhaler' and face-mask in young asthmatic children , 1990, The Lancet.

[19]  G. Smaldone,et al.  Choice of mechanical ventilator: influence on nebulizer performance , 1993 .

[20]  P. Morrow,et al.  Chemical breakdown of technetium-99m DTPA during nebulization. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  A. Clark The use of laser diffraction for the evaluation of the aerosol clouds generated by medical nebulizers , 1995 .

[22]  B. M. Wright A new nebuliser. , 1958, Lancet.

[23]  J. Stjernswärd,et al.  Lung cancer--a worldwide health problem. , 1989, Chest.

[24]  I. Kellaway,et al.  PARTICLE SIZE ANALYSIS OF NEBULISED AEROSOLS USING FRAUNHOFER LASER DIFFRACTION AND INERTIAL COMPACTION METHODS , 1986 .

[25]  C. O’Callaghan,et al.  PARADOXICAL DETERIORATION IN LUNG FUNCTION AFTER NEBULISED SALBUTAMOL IN WHEEZY INFANTS , 1986, The Lancet.

[26]  J. H. Bell,et al.  Variation in delivery of isoprenaline from various pressurized inhalers. , 1973, The Journal of pharmacy and pharmacology.

[27]  S. S. Davis,et al.  Physico-chemical studies on aerosol solutions for drug delivery I. Water-propylene glycol systems , 1978 .

[28]  D. Muir,et al.  Aerosol deposition and airway obstruction. , 1976, The American review of respiratory disease.

[29]  G. Persson,et al.  The bronchodilator response from inhaled terbutaline is influenced by the mass of small particles: a study on a dry powder inhaler (Turbuhaler). , 1989, The European respiratory journal.

[30]  H. Hansson,et al.  Why do medical nebulizers differ in their output and particle size characteristics? , 1994, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[31]  Abramson Ha Principles and, practice of aerosol therapy of the lungs and bronchi. , 1946 .

[32]  J. H. Vincent,et al.  On the practical significance of electrostatic lung deposition of isometric and fibrous aerosols , 1985 .

[33]  R. Steigbigel,et al.  Factors determining pulmonary deposition of aerosolized pentamidine in patients with human immunodeficiency virus infection. , 1991, The American review of respiratory disease.

[34]  G. K. Adams,et al.  The effect of aerosol distribution on airway responsiveness to inhaled methacholine in patients with asthma. , 1992, The Journal of allergy and clinical immunology.

[35]  A. Milner,et al.  Comparison of nebulised aerosol deposition in the lungs of healthy adults following oral and nasal inhalation. , 1993, Thorax.

[36]  B. Lipworth,et al.  Single dosing comparison of the relative cardiac beta 1/beta 2 activity of inhaled fenoterol and salbutamol in normal subjects. , 1993, Thorax.

[37]  S. Shire,et al.  Assessment of aerosol delivery systems for recombinant human deoxyribonuclease , 1994 .

[38]  S. Clarke,et al.  The nasal distribution of metered does inhalers , 1987, The Journal of Laryngology & Otology.

[39]  D. Pavia,et al.  ASSESSMENT OF JET NEBULISERS FOR LUNG AEROSOL THERAPY , 1983, The Lancet.

[40]  C. O’Callaghan,et al.  Improvement in sodium cromoglycate delivery from a spacer device by use of an antistatic lining, immediate inhalation, and avoiding multiple actuations of drug. , 1993, Thorax.

[41]  T. T. Mercer,et al.  Production and characterization of aerosols. , 1973, Archives of internal medicine.

[42]  B. Lipworth,et al.  New perspectives on inhaled drug delivery and systemic bioactivity , 1995 .

[43]  M. O'Doherty,et al.  Pulmonary deposition of nebulised pentamidine isethionate: effect of nebuliser type, dose, and volume of fill. , 1990, Thorax.

[44]  S. Newman,et al.  Lung deposition from four nebulizers. , 1993, Respiratory medicine.

[45]  D. Pavia,et al.  Factors influencing the size distribution of aerosols from jet nebulisers. , 1983, Thorax.

[46]  P. L. Souef,et al.  Dilution of nebulised aerosols by air entrainment in children , 1990, The Lancet.

[47]  J. Bateman,et al.  Is driving gas flow rate clinically important for nebulizer therapy? , 1986, British journal of diseases of the chest.

[48]  W Stahlhofen,et al.  Experimental determination of the regional deposition of aerosol particles in the human respiratory tract. , 1980, American Industrial Hygiene Association journal.

[49]  M. Dahlbäck,et al.  Basic nebulizer function. , 1994, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[50]  J. Fleming,et al.  Fractional deposition from a jet nebulizer: how it differs from a metered dose inhaler. , 1985, British journal of diseases of the chest.

[51]  M. O'Doherty,et al.  Which apparatus for inhaled pentamidine? A comparison of pulmonary deposition via eight nebulisers. , 1991, The European respiratory journal.

[52]  E. Juniper,et al.  Standardization of inhalation provocation tests: influence of nebulizer output, particle size, and method of inhalation. , 1981, The Journal of allergy and clinical immunology.

[53]  M. Newhouse,et al.  Aerosol penetration into the lung; influence on airway responses. , 1981, Chest.

[54]  Gerald C. Smaldone,et al.  Mechanisms of aerosol deposition in a nasal model , 1985 .

[55]  P. L. Souëf,et al.  Validity of methods used to test airway responsiveness in children , 1992, The Lancet.

[56]  I. Gonda,et al.  Targeting by deposition , 1992 .

[57]  S. Pedersen,et al.  The influence of orally deposited budesonide on the systemic availability of budesonide after inhalation from a Turbuhaler. , 1993, British journal of clinical pharmacology.

[58]  D. Pavia,et al.  Effect of aerosol particle size on bronchodilatation with nebulised terbutaline in asthmatic subjects. , 1986, Thorax.

[59]  S. Spiro,et al.  Comparison of bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurised metered dose inhaler, as a dry powder, and as a nebulised solution. , 1990, Thorax.

[60]  J. Mao,et al.  An open, prospective comparison of beta 2 agonists given via nebuliser, Nebuhaler, or pressurised inhaler by ambulance crew as emergency treatment. , 1995, Thorax.

[61]  S. Clarke,et al.  Evaluation of jet nebulisers for use with gentamicin solution. , 1985, Thorax.

[62]  S. Clarke,et al.  Delivery of albuterol and ipratropium bromide from two nebulizer systems in chronic stable asthma. Efficacy and pulmonary deposition. , 1989, Chest.

[63]  S. Holgate,et al.  Bronchoconstrictor properties of preservatives in ipratropium bromide (Atrovent) nebuliser solution. , 1987, British medical journal.

[64]  M. Knowles,et al.  Recent advances in aerosol therapy. , 1994, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[65]  P. Hurley,et al.  Assessment of antibiotic aerosol generation using commercial jet nebulizers. , 1994, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[66]  A. Milner,et al.  Drug delivery from jet nebulisers. , 1992, Archives of disease in childhood.

[67]  H. Chrystyn,et al.  Determination of the relative bioavailability of salbutamol to the lung following inhalation. , 1992, British journal of clinical pharmacology.

[68]  S. Newman,et al.  Aerosol deposition considerations in inhalation therapy. , 1985, Chest.

[69]  J. G. Douglas,et al.  A comparative study of two doses of salbutamol nebulized at 4 and 8 litres per minute in patients with chronic asthma. , 1986, British journal of diseases of the chest.

[70]  H. Nelson,et al.  Extreme variability in aerosol output of the DeVilbiss 646 jet nebulizer. , 1991, Chest.

[71]  B. Lipworth,et al.  Nebuliser performance, pharmacokinetics, airways and systemic effects of salbutamol given via a novel nebuliser delivery system ("Ventstream"). , 1994, Thorax.

[72]  I. Gonda,et al.  Evaporation of aqueous aerosols produced by jet nebulizers: effects on particle size and concentration of solution in the droplets. , 1994, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[73]  Hatch Tf,et al.  Deposition and retention models for internal dosimetry of the human respiratory tract. Task group on lung dynamics. , 1966 .

[74]  G. Borsboom,et al.  Changes of nebulizer output over the years. , 1992, The European respiratory journal.

[75]  G F Alvine,et al.  Disposable jet nebulizers. How reliable are they? , 1992, Chest.

[76]  D. Hendrick,et al.  Jet and ultrasonic nebuliser output: use of a new method for direct measurement of aerosol output. , 1990, Thorax.

[77]  A. Taylor,et al.  Ultrasonic Nebulisation of Fluids with Different Viscosities and Surface Tensions , 1995 .

[78]  D. Geddes,et al.  Pulmonary deposition of nebulised amiloride in cystic fibrosis: comparison of two nebulisers. , 1991, Thorax.

[79]  P. Barry,et al.  Multiple actuations of salbutamol MDI into a spacer device reduce the amount of drug recovered in the respirable range. , 1994, The European respiratory journal.

[80]  D. Smith,et al.  Comparison of Nebuliser Efficiency for Aerosolizing Pentamidine , 1992, The Journal of pharmacy and pharmacology.

[81]  S. Clarke,et al.  Wastage of drug from nebulisers: A review , 1987, Journal of the Royal Society of Medicine.

[82]  G. Smaldone Drug delivery by nebulization: "reality testing". , 1994, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[83]  S. Lakshminarayan,et al.  Efficiency of air compressor-driven nebulizers. , 1985, Chest.

[84]  G. Rudolf,et al.  Modelling and algebraic formulation of regional aerosol deposition in man , 1990 .

[85]  D. Mitchell,et al.  Effect of particle size of bronchodilator aerosols on lung distribution and pulmonary function in patients with chronic asthma. , 1987, Thorax.

[86]  C. O’Callaghan,et al.  Spacer device with face mask attachment for giving bronchodilators to infants with asthma. , 1989, BMJ.